DCPH Deciphera Pharmaceuticals Inc.

23.45
+0.48  (+2%)
Previous Close 22.97
Open 22.95
Price To Book 3.2
Market Cap 895533269
Shares 38,189,052
Volume 283,187
Short Ratio
Av. Daily Volume 164,431

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 additional data due 2019.
DCC-3014
Solid tumors or hematological malignancies
Phase 3 data due mid-2019.
DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 1 update at ESMO October 2018. ORR 21%, PFS 40 weeks - 2nd/3rd line.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 1 expansion data due 2019.
DCC-2618
Gastrointestinal Stromal Tumors (GIST)
Phase 3 trial initiation announced December 20, 2018.
DCC-2618 - INTRIGUE
Gastrointestinal Stromal Tumors (GIST) - second-line
Phase 1b trial complete.
Rebastinib
Breast Cancer
Phase 1b/2 initial data due 2019.
Rebastinib and paclitaxel
Solid tumors
Phase 1b/2 trial initiation announced January 3, 2019.
Rebastinib and carboplatin
Solid tumors

Latest News

  1. Imagine Owning Deciphera Pharmaceuticals (NASDAQ:DCPH) And Wondering If The 16% Share Price Slide Is Justified
  2. Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results
  3. Market Trends Toward New Normal in Exelon, AT&T, United States Cellular, Deciphera Pharmaceuticals, Boyd Gaming, and Argo Group International — Emerging Consolidated Expectations, Analyst Ratings
  4. Deciphera CEO resigns, Ex-Agios exec to take over
  5. Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D.
  6. Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day
  7. Deciphera Pharmaceuticals Shares March Higher, Can It Continue?
  8. Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
  9. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors
  10. Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans
  11. Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
  12. Report: Developing Opportunities within AutoZone, Deciphera Pharmaceuticals, Clearwater Paper, Churchill Downs, Whitestone REIT, and ZTO Express (Cayman) — Future Expectations, Projections Moving into 2019
  13. Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)
  14. Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?
  15. Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference
  16. Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
  17. Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results
  18. Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors
  19. Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress